Rapid viral rebound after 4 years of suppressive therapy in a seronegative HIV-1 infected infant treated from birth

Pediatric Infectious Disease Journal

Volumn 34, Issue 3, 2015, Pages e48-e51

  Butler, Karina M ^a,b   Gavin, Patrick ^a   Coughlan, Suzie ^c   Rochford, Annette ^a   Mc Donagh, Sinead ^a   Cunningham, Orla ^d   Poulsom, Hannah ^e   Watters, Sarah A ^e   Klein, Nigel ^e  

^a OUR LADY S CHILDREN S HOSPITAL   (Ireland)

^b UNIVERSITY COLLEGE DUBLIN   (Ireland)

^c UNIVERSITY COLLEGE DUBLIN   (Ireland)

^d Tallaght and Coombe Women's and Infant's University Hospital   (Ireland)

^e UNIVERSITY COLLEGE LONDON   (United Kingdom)

Author keywords

Early ARV treatment; HIV 1; Seronegative infected infant; Viral rebound

Indexed keywords

LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; PHENOBARBITAL; VIRUS DNA; VIRUS RNA; ZIDOVUDINE;

ANTIVIRAL THERAPY; ARTICLE; BLOOD SAMPLING; CASE REPORT; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MEDICATION COMPLIANCE; POLYMERASE CHAIN REACTION; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; VIRUS LOAD; WITHDRAWAL SYNDROME; DRUG EFFECTS; GENETICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HIV INFECTIONS; NEWBORN; PRESCHOOL CHILD; TIME; TREATMENT FAILURE; TREATMENT OUTCOME; VIROLOGY;

ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CHILD, PRESCHOOL; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; INFANT; INFANT, NEWBORN; TIME FACTORS; TREATMENT FAILURE; TREATMENT OUTCOME; VIRAL LOAD;

EID: 84924159785     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0000000000000570     Document Type: Article

References (15)

1. Persaud D, Gay H, Ziemniak C, et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N Engl J Med. 2013;369:1828-1835.
2. Payne H, Mkhize N, Morris L et al. Routine antibody tests have no place in determining HIV status after early ART: evidence from CHER. Abstract 922. Top Antivir Med. 2014;22:482.
3. Luzuriaga K, McManus M, Catalina M, et al. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: control of viral replication and absence of persistent HIV-1-specific immune responses. J Virol. 2000;74:6984-6991.
4. Luzuriaga K, Tabak B, Garber M et al. HIV type 1 (HIV-1) reservoirs decay continuously under sustained virologic control in HIV-1 infected children who received early treatment. J Infect Dis 2014;210:1529-1538.
5. Persaud D, Patel K, Karallus B et al. Virologic control by 1 year of age significantly reduces HIV-1 reservoirs in perinatal infection. Abstract 72. Top Antivir Med 2014;22:35-36.
6. Persaud D, Ray SC, Kajdas J, et al. Slow human immunodeficiency virus type 1 evolution in viral reservoirs in infants treated with effective antiretroviral therapy. AIDS Res Hum Retroviruses. 2007;23:381-390.
7. Persaud D, Deveikis, Gay H et al. Very early combination antriretroviral therapy in perinatal HIV-1 infection: two cases. Abstract 75LB. Top Antivir Med 2014;22:126.
8. Ferguson W, Goode M, Walsh A, et al. Evaluation of 4 weeks' neonatal antiretroviral prophylaxis as a component of a prevention of mother-to-child transmission program in a resource-rich setting. Pediatr Infect Dis J. 2011;30:408-412.
9. Sharland M, Blanche S, Castelli G, et al.; PENTA Steering Committee. PENTA guidelines for the use of antiretroviral therapy, 2004. HIV Med. 2004;5(suppl 2):61-86.
10. NIH news press release Thursday July10th, 2014. "Mississippi Baby" now has detectable virus, researchers find. http://www.niaid.nih.gov/news/newsreleases/2014/Pages/MississippiBabyHIV.aspx
11. Panel on antiretroviral therapy and medical management of HIV-infected children: guidelines for the use of antiretroviral agents in pediatric HIV infection. Available at: http://aidsinfo.nih.gov/contentfiles/Ivguidelines/pediatricguidelines.pdf. Accessed June 23, 2014.
12. ARROW Trial team. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial Lancet. 2013;381:1391-1403.
13. Penazzato M, Prendergast AJ, Muhe LM, et al. Optimisation of antiretroviral therapy in HIV-infected children under 3 years of age. Cochrane Database Syst Rev 2014, Issue 5. Art. No.: CD004772. DOI: 10.1002/14651858.CD004772.pub4.
14. Zanchetta M, Anselmi A, Vendrame D, et al. Early therapy in HIV-1-infected children: effect on HIV-1 dynamics and HIV-1-specific immune response. Antivir Ther. 2008;13:47-55.
15. Klein N, Sefe D, Mosconi I, et al.; Paediatric European Network for Treatment of AIDS 11 Trial Team. The immunological and virological consequences of planned treatment interruptions in children with HIV infection. PLoS One. 2013;8:e76582.